Multiple Myeloma
A non-interventional observational post authorisation safety study of subjects treated with lenalidomide
Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma after at least 2 prior treatment regimens
Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With relapsed or refractory Multiple Myeloma
Myeloma IX is intended to be a unifying trial addressing issues in patients of all ages and providing a strategy within which to introduce new treatments as they become available. There are, however, two distinct treatment pathways. i) Intensive pathway:
For younger/fitter patients where intensive HDT with stem cell support
ii) Non-intensive pathway: considered appropriate. Although the previous MRC Myeloma VII trial, in which there was randomisation to HDT, was restricted to patients under the age of 65, it is recognised that fit patients over this age may wish to receive the more intensive treatment, and the decision with regard to which pathway to follow will be a matter for discussion between the treating clinician and the patient.
is considered appropriate.